Skip to main content

Table 6 Incidence of complications secondary to diabetes mellitus in patients from 2018 to 2022

From: Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico

Type of complication

Between 2018 and 2022

2018 (%)

2019 (%)

2020 (%)

2021 (%)

2022 (%)

p-value

Microvascular complications

Diabetic neuropathy

35 (3.6)

n = 967

4 (0.4)

n = 967

7 (0.7)

n = 967

6 (0.6)

n = 967

15 (1.6)

n = 967

7 (0.7)

n = 967

0.106

Diabetic nephropathy

22 (2.2)

n = 967

5 (0.5)

n = 967

2 (0.2)

n = 967

6 (0.6)

n = 967

7 (0.7)

n = 967

3 (0.3)

n = 967

0.442

Diabetic retinopathy

16 (1.7)

n = 967

3 (0.3)

n = 967

3 (0.3) n = 967

1 (0.1)

n = 967

3 (0.3)

n = 967

5 (0.5)

n = 967

0.615

Diabetic foot

5 (0.5)

n = 967

1 (0.1)

n = 967

2 (0.2)

n = 967

0 (0)

n = 967

1 (0.1)

n = 967

0 (0)

n = 967

0.478

Acute complications

Hypoglycemia

14 (1.4)

n = 967

2 (0.2) n = 967

3 (0.3) n = 964

5 (0.5)

n = 967

4 (0.4)

n = 967

3 (0.3)

n = 967

0.804

Hyperosmolar hyperglycemic state

6 (0.6)

n = 967

0 (0)

n = 967

1 (0.1)

n = 964

2 (0.2)

n = 967

1 (0.1)

n = 967

2 (0.2)

n = 967

0.675

Diabetic ketoacidosis

2 (0.2)

n = 967

0 (0)

n = 967

0 (0)

n = 964

0 (0)

n = 967

0 (0)

n = 967

1 (0.1)

n = 967

0.406

Macrovascular complications

Ischemic heart disease

11 (1.1)

n = 967

2 (0.2)

n = 967

1 (0.1)

n = 967

2 (0.2) n = 967

4 (0.4)

n = 967

2 (0.2)

n = 967

0.702

Ischemic stroke

4 (0.4)

n = 967

1 (0.1)

n = 967

1 (0.1)

n = 967

0 (0)

n = 967

1 (0.1)

n = 967

1 (0.1)

n = 967

0.91

  1. A p-value was obtained through the Cochran's Q test. A p-value < 0.05 was considered statistically significant